{"gene":"BRCA1","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1999,"finding":"Brca1-deficient mouse embryonic stem cells have impaired repair of chromosomal DNA double-strand breaks (DSBs) by homologous recombination, with altered relative frequencies of homologous vs. nonhomologous DNA integration and DSB repair, demonstrating a caretaker role for BRCA1 in promoting homologous recombination and limiting mutagenic nonhomologous repair.","method":"Genetic knockout in mouse embryonic stem cells with DSB repair frequency assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype (HR frequency measurement), replicated conceptually across multiple labs","pmids":["10549283"],"is_preprint":false},{"year":2000,"finding":"ATR phosphorylates BRCA1 on six Ser/Thr residues including Ser1423 in vitro and in vivo in response to UV light, hydroxyurea, aphidicolin, and partially in response to ionizing radiation. ATR and BRCA1 co-localize in nuclear foci at stalled replication forks, placing them in the same genotoxic stress-responsive pathway.","method":"In vitro kinase assay, kinase-inactive ATR dominant-negative expression, immunofluorescence co-localization of nuclear foci","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro phosphorylation assay plus dominant-negative in-cell validation, multiple orthogonal methods in one study","pmids":["11114888"],"is_preprint":false},{"year":2002,"finding":"BRCA1 colocalizes with markers of the inactive X chromosome (Xi) in female somatic cells and physically associates with XIST RNA as detected by chromatin immunoprecipitation. BRCA1-deficient cells show defects in Xi chromatin structure and XIST RNA concentration; reconstitution of BRCA1-deficient cells with wild-type BRCA1 restored focal XIST RNA staining and reduced re-expression of a silenced Xi-located GFP transgene.","method":"Chromatin immunoprecipitation, immunofluorescence, BRCA1 reconstitution in deficient cells, GFP reporter assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, reconstitution experiment, and functional reporter assay in a single study with multiple orthogonal methods","pmids":["12419249"],"is_preprint":false},{"year":2003,"finding":"The purified BRCA1/BARD1 complex, together with E1 and UbcH5a, is sufficient to reconstitute monoubiquitination of FANCD2 in vitro. However, siRNA-mediated knockdown of BRCA1 in human cells does not lead to a defect in FANCD2 ubiquitination, and ablation of RING finger domains of BRCA1 or BARD1 in DT40 cells leaves FANCD2 modification intact. BRCA1 affects accumulation of FANCD2 at DNA damage sites but BRCA1/BARD1 E3 ligase activity is not essential for FANCD2 monoubiquitination in vivo.","method":"In vitro ubiquitination reconstitution, siRNA knockdown, RING domain ablation in DT40 cells","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution plus genetic ablation in cells, two orthogonal methods establishing a negative result in vivo","pmids":["12887909"],"is_preprint":false},{"year":2003,"finding":"BRCA1 interacts with processive (hyperphosphorylated, IIO form) RNA polymerase II rather than the hypophosphorylated promoter-associated form (IIA) in undamaged cells. BRCA1-RNA pol II complexes are highly functional in transcriptional run-off assays and the interaction is disrupted by DNA-damaging agents.","method":"Fractionation, co-immunoprecipitation, transcriptional run-off assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with functional run-off assay, single lab, two orthogonal methods","pmids":["14506230"],"is_preprint":false},{"year":2004,"finding":"BRCA1 interacts and colocalizes with topoisomerase IIα in S-phase cells. BRCA1-deficient cells show lagging chromosomes and defective DNA decatenation in vitro, phenocopying topoisomerase IIα inhibition. Topoisomerase IIα is ubiquitinated in a BRCA1-dependent manner, and its ubiquitination correlates with higher DNA decatenation activity.","method":"Co-immunoprecipitation, co-localization, in vitro decatenation assay, ubiquitination assay in BRCA1-deficient cells","journal":"Nature structural & molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vitro functional assay and ubiquitination assay, single lab","pmids":["15965487"],"is_preprint":false},{"year":2004,"finding":"BRCA1 RING and BRCT domains cooperate to target BRCA1 to ionizing radiation-induced nuclear foci. Cancer mutations in the BRCT domain abolish recruitment. A RING-BRCT fusion restores foci targeting, co-localizes with MDC1, and inhibits entry of endogenous BRCA1 into foci. Neither RING nor BRCT domain alone is sufficient for targeting.","method":"YFP-tagged domain mapping, live-cell fluorescence imaging, ionizing radiation treatment, co-localization with MDC1","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct imaging of tagged BRCA1 fragments with cancer mutation controls, single lab","pmids":["15569676"],"is_preprint":false},{"year":2007,"finding":"CCDC98 (Abraxas) is a component of the BRCA1-RAP80 complex that mediates BRCA1's association with RAP80, controls DNA damage-induced formation of BRCA1 foci, and is required for BRCA1-dependent G2/M checkpoint activation.","method":"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci analysis, checkpoint assay","journal":"Nature structural & molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional checkpoint assay, single lab","pmids":["17643121"],"is_preprint":false},{"year":2008,"finding":"BRCA1 binds the SIRT1 promoter and increases SIRT1 expression, which in turn inhibits Survivin by altering epigenetic modification of histone H3. Absence of SIRT1 blocks BRCA1's regulation of Survivin.","method":"Chromatin immunoprecipitation, promoter reporter assay, siRNA knockdown, Western blot, mouse tumor model","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP at SIRT1 promoter plus epistasis knockdown experiment, single lab","pmids":["18851829"],"is_preprint":false},{"year":2009,"finding":"BRCA1-associated protein 1 (BAP1) interacts with the RING finger domain of BARD1 and interferes with the BRCA1/BARD1 E3 ligase association via surface plasmon resonance. BAP1 inhibits BRCA1 autoubiquitination and NPM1/B23 ubiquitination by BRCA1/BARD1. A catalytically inactive BAP1 mutant (C91S) still inhibits ubiquitination, indicating a second non-catalytic inhibitory mechanism.","method":"Co-immunoprecipitation, BIAcore surface plasmon resonance, in vitro ubiquitination assay, catalytically inactive mutant (C91S), shRNA knockdown","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of ubiquitination with mutagenesis (C91S) and biophysical binding assay, multiple orthogonal methods in one study","pmids":["19117993"],"is_preprint":false},{"year":2009,"finding":"MERIT40 (a 40 kDa protein) assembles into the RAP80/CCDC98-containing BRCA1-A complex via direct interaction with BRE/BRCC45, and is required for maintaining stability of BRE and the five-subunit complex at DNA damage sites, thereby regulating BRCA1 retention at DNA breaks and checkpoint function.","method":"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci analysis, checkpoint assay","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional foci and checkpoint assays, single lab","pmids":["19261748"],"is_preprint":false},{"year":2009,"finding":"BRCA1 overexpression reduces acetylation of estrogen receptor-α (ER-α) and increases mono-ubiquitination of ER-α; a BRCA1 mutant defective for ubiquitin ligase activity (I26A) failed to ubiquitinate ER-α or repress its transcriptional activity in vivo. Wild-type BRCA1 but not cancer mutant C61G inhibited p300-mediated acetylation of ER-α in vitro.","method":"In vitro ubiquitination assay, in vitro acetylation assay, siRNA knockdown, overexpression of BRCA1 ubiquitin-ligase-dead mutant (I26A), Western blot","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro assay plus active-site mutant (I26A), single lab, multiple orthogonal methods","pmids":["19887647"],"is_preprint":false},{"year":2010,"finding":"BRCA1 assembles with complexes containing E2F-1 and RB to form a repressive multicomponent transcriptional complex that inhibits BRCA1 promoter transcription (autoregulatory loop). Genotoxic stress disrupts this complex, displacing BRCA1 from its own promoter and upregulating BRCA1 transcription. Tandem ChIP confirmed the BRCA1/E2F1/Rb complex at the BRCA1 promoter in vivo.","method":"Chromatin immunoprecipitation (sequential/tandem ChIP), promoter-reporter assay, BRCA1 knockdown and overexpression","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tandem ChIP plus functional reporter and BRCA1 depletion/overexpression, single lab","pmids":["20068145"],"is_preprint":false},{"year":2019,"finding":"RNF168 acts redundantly with BRCA1 to load PALB2 onto damaged DNA. Loss of RNF168 negates synthetic rescue of BRCA1 deficiency by 53BP1 deletion. Forced targeting of PALB2 to DNA breaks circumvents BRCA1 haploinsufficiency. BRCA1 promotes two distinct steps of homologous recombination: DNA end resection (counteracting 53BP1) and RAD51 loading (via PALB2 recruitment).","method":"Genetic epistasis (double and triple KO mice), RAD51 foci assay, PARP inhibitor sensitivity, forced PALB2 targeting","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis in mouse models plus cell-based RAD51 foci and PARP inhibitor assays, multiple orthogonal methods","pmids":["30704900"],"is_preprint":false},{"year":2020,"finding":"BRCA1 promotes two genetically separable activities in homologous recombination: (1) counteracting 53BP1-RIF1-Shieldin to promote DNA end resection (via the coiled-coil domain) and (2) promoting RAD51 loading (via the Δ11 region). Brca1CC and Brca1Δ11 alleles are separation-of-function mutations that complement each other to provide sufficient HR for normal development.","method":"Mouse genetics (Brca1CC/Δ11 compound heterozygotes), HR assays, RAD51 foci, 53BP1-RIF1 epistasis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with separation-of-function alleles in mice, multiple functional readouts, rigorous controls","pmids":["32359443"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structure of BRCA1-BARD1 bound to nucleosome revealed that ankyrin repeat and tandem BRCT domains in BARD1 bind nucleosomal histones, DNA, and monoubiquitin on H2A K13/K15 (DSB-specific marks). RING domains in BRCA1-BARD1 orient an E2 ubiquitin-conjugating enzyme atop the nucleosome for ubiquitin transfer to flexible C-terminal tails of H2A/H2AX. Recognition of N-terminal H2A monoubiquitin blocks polyubiquitin chain formation and cooperatively promotes C-terminal H2A ubiquitylation, opposing 53BP1.","method":"Cryo-electron microscopy, biochemical ubiquitylation assays, structure-guided mutational analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structure with functional validation by mutagenesis and in vitro ubiquitylation assays in one rigorous study","pmids":["34321665"],"is_preprint":false},{"year":2021,"finding":"SIRT2 deacetylase complexes with BRCA1-BARD1 and deacetylates conserved lysines in the BARD1 RING domain at the BRCA1-BARD1 interface, promoting BRCA1-BARD1 heterodimerization, mutual stability, nuclear retention, localization to DNA damage sites, and efficient homologous recombination.","method":"Co-immunoprecipitation, deacetylation assay, SIRT2 knockdown/knockout, HR assay, immunofluorescence foci analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional HR and foci assays with deacetylation biochemistry, single lab","pmids":["33789098"],"is_preprint":false},{"year":2021,"finding":"BRCA1 associates with centromeric chromatin in an R-loop-dependent manner and counteracts accumulation of R-loops at centromeric α-satellite repeats. BRCA1-deficient cells show impaired CENP-A localization, increased centromeric RNA transcription, increased centromeric breakage, acentric micronuclei, and Rad52-dependent hyper-recombination at centromeric satellites, all R-loop-dependent.","method":"Chromatin immunoprecipitation, immunofluorescence, BRCA1 knockdown, R-loop detection (DRIP), micronuclei scoring, Rad52 epistasis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus KD with multiple functional readouts and epistasis, single lab","pmids":["34599155"],"is_preprint":false},{"year":1999,"finding":"Casein kinase 2 (CK2) β-subunit associates with the carboxy-terminal region of BRCA1 (yeast two-hybrid and Sf9 cell confirmation) and phosphorylates BRCA1 in vitro at Ser1572; the cancer-associated missense mutation M1775R in BRCA1 weakens the CK2β association.","method":"Yeast two-hybrid, in vitro kinase assay, site-directed mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, yeast two-hybrid plus in vitro kinase assay without in-cell validation","pmids":["10403822"],"is_preprint":false},{"year":2000,"finding":"BRCA1 physically associates with ATF1 (a CREB/ATF transcription factor) via the BRCA1 RING finger domain in vitro, in yeast, and in human cells. BRCA1 stimulates transcription from a CRE reporter gene and from the TNF-α promoter in a CRE-dependent manner.","method":"Yeast two-hybrid, co-immunoprecipitation, in vitro binding, transient transfection reporter assay","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, yeast two-hybrid and Co-IP plus reporter assay, no mutagenesis confirming RING-ATF1 interface in cells","pmids":["10945975"],"is_preprint":false},{"year":2004,"finding":"DNA damage (ionizing radiation) induces BRCA1 nuclear export in a dose-dependent, CRM1-dependent manner that also requires wild-type p53 function. BRCA1 nuclear export occurs across all cell cycle phases, representing a p53-dependent regulatory mechanism of BRCA1 localization in response to DNA damage.","method":"Immunohistochemical staining, subcellular fractionation and Western blot, CRM1 inhibitor (leptomycin B), p53 inactivation by HPV E6, tetracycline-inducible p53 system","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation with functional inhibitors and two independent cell systems, single lab","pmids":["15087457"],"is_preprint":false},{"year":2024,"finding":"BRCA1 promotes transcription of both VDAC3 and GPX4; BRCA1 deficiency blocks VDAC3-dependent erastin-induced ferroptosis but sensitizes cells to GPX4 inhibitor-induced ferroptosis. NCOA4-mediated ferritinophagy and defective GPX4 induction synergize PARPi and GPX4 inhibition to induce ferroptosis in BRCA1-deficient cancer cells.","method":"Transcriptional reporter assay, ChIP, cell viability assays with GPX4i and PARPi, NCOA4 knockdown, xenograft models","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional ferroptosis assays with multiple inhibitors and in vivo xenograft model, single lab","pmids":["38552003"],"is_preprint":false}],"current_model":"BRCA1 is a multifunctional nuclear tumor suppressor that forms a RING-domain E3 ubiquitin ligase heterodimer with BARD1 (whose nucleosome-recognition and ubiquitylation mechanism has been resolved by cryo-EM) and assembles into distinct protein complexes—including the RAP80/Abraxas/MERIT40-containing BRCA1-A complex—that are recruited to DNA double-strand breaks marked by H2A-K13/K15 monoubiquitin; at breaks, BRCA1 promotes homologous recombination through two separable activities—counteracting 53BP1-RIF1-Shieldin to enable DNA end resection, and collaborating with RNF168 to load PALB2/BRCA2/RAD51—while also being phosphorylated by ATM and ATR at multiple sites (including Ser1423) to coordinate checkpoint signaling, ubiquitylating substrates such as topoisomerase IIα and ER-α to regulate DNA decatenation and hormone receptor activity respectively, maintaining centromere stability by resolving R-loops at α-satellite repeats, supporting XIST RNA concentration on the inactive X chromosome, and autoregulating its own transcription through a repressive BRCA1/E2F1/Rb complex that is dissolved upon genotoxic stress."},"narrative":{"mechanistic_narrative":"BRCA1 is a multifunctional nuclear tumor suppressor that safeguards genome integrity by promoting error-free homologous recombination (HR) repair of DNA double-strand breaks and limiting mutagenic nonhomologous repair [PMID:10549283]. It executes HR through two genetically separable activities: a coiled-coil-dependent function that counteracts the 53BP1-RIF1-Shieldin axis to license DNA end resection, and a Δ11-region/PALB2-dependent function that loads RAD51 onto resected DNA, with RNF168 acting redundantly with BRCA1 in the PALB2-loading step [PMID:30704900, PMID:32359443]. BRCA1 functions as a RING-domain heterodimer with BARD1; cryo-EM of the BRCA1-BARD1–nucleosome complex shows BARD1 ankyrin and BRCT domains reading nucleosomal histones, DNA, and the DSB-specific H2A K13/K15 monoubiquitin mark while the RING domains position an E2 enzyme for C-terminal H2A ubiquitylation that opposes 53BP1 [PMID:34321665]. Recruitment to ionizing-radiation-induced foci requires cooperation of the BRCA1 RING and BRCT domains and co-localization with MDC1, with cancer mutations abolishing targeting [PMID:15569676], and BRCA1 retention at breaks is organized by the RAP80/Abraxas(CCDC98)/MERIT40-containing BRCA1-A complex, which controls foci formation and the G2/M checkpoint [PMID:17643121, PMID:19261748]. Heterodimer assembly and DNA-damage localization are tuned by SIRT2-mediated deacetylation of the BARD1 RING interface, while BAP1 antagonizes the BRCA1/BARD1 ligase through both catalytic and non-catalytic mechanisms [PMID:33789098, PMID:19117993]. As an E3 ubiquitin ligase BRCA1/BARD1 modifies substrates including topoisomerase IIα, regulating DNA decatenation and chromosome segregation [PMID:15965487], and estrogen receptor-α, repressing its transcriptional activity [PMID:19887647]. BRCA1 activity is integrated into genotoxic stress signaling through ATR phosphorylation of multiple residues including Ser1423 at stalled replication forks [PMID:11114888] and through p53/CRM1-dependent nuclear export after DNA damage [PMID:15087457]. Beyond repair, BRCA1 maintains centromere stability by resolving R-loops at α-satellite repeats to preserve CENP-A loading [PMID:34599155], supports XIST RNA concentration and chromatin structure on the inactive X chromosome [PMID:12419249], and acts as a transcriptional regulator—autorepressing its own promoter via a BRCA1/E2F1/Rb complex dissolved by genotoxic stress [PMID:20068145] and controlling target genes such as SIRT1 and the ferroptosis regulators VDAC3 and GPX4 [PMID:18851829, PMID:38552003].","teleology":[{"year":1999,"claim":"Established BRCA1's foundational caretaker role by showing it is required for accurate double-strand break repair rather than acting indirectly, defining the genome-stability function that frames all later mechanism.","evidence":"Brca1 knockout mouse embryonic stem cells with DSB repair frequency assays","pmids":["10549283"],"confidence":"High","gaps":["Did not identify the molecular partners executing HR","Did not separate resection from RAD51-loading roles"]},{"year":2000,"claim":"Placed BRCA1 downstream of replication-stress and damage signaling by identifying ATR as a kinase that phosphorylates it at defined residues, linking BRCA1 localization to the genotoxic checkpoint machinery.","evidence":"In vitro kinase assay, dominant-negative kinase-inactive ATR, foci co-localization at stalled forks","pmids":["11114888"],"confidence":"High","gaps":["Functional consequence of each phosphosite not fully resolved","Relationship to ATM-dependent sites not addressed here"]},{"year":2002,"claim":"Extended BRCA1 function beyond break repair to chromatin maintenance, showing it associates with XIST RNA and is needed for inactive-X chromatin integrity.","evidence":"ChIP, immunofluorescence, BRCA1 reconstitution, silenced GFP reporter on Xi","pmids":["12419249"],"confidence":"High","gaps":["Direct vs. indirect role in XIST localization unresolved","Mechanism connecting BRCA1 to XIST concentration unknown"]},{"year":2003,"claim":"Clarified the in vivo relevance of BRCA1/BARD1 E3 ligase activity by demonstrating that, despite reconstituting FANCD2 monoubiquitination in vitro, the ligase is dispensable for that modification in cells, tightening claims about its physiological substrates.","evidence":"In vitro ubiquitination reconstitution, siRNA knockdown, RING ablation in DT40 cells","pmids":["12887909"],"confidence":"High","gaps":["The bona fide essential in vivo substrates of BRCA1/BARD1 left undefined","How BRCA1 affects FANCD2 accumulation at damage sites without ubiquitinating it unclear"]},{"year":2004,"claim":"Defined the domain logic of BRCA1 recruitment, showing RING and BRCT domains must cooperate for foci targeting and that cancer mutations disrupt this, linking genotype to localization failure.","evidence":"YFP-tagged domain mapping, live-cell imaging after IR, MDC1 co-localization","pmids":["15569676"],"confidence":"Medium","gaps":["Direct ligand bound by the cooperating domains not defined here","Single lab, imaging-based"]},{"year":2004,"claim":"Identified topoisomerase IIα as a BRCA1-dependent ubiquitination target and connected BRCA1 to chromosome segregation through DNA decatenation, broadening its mechanistic repertoire beyond HR.","evidence":"Co-IP, co-localization, in vitro decatenation assay, ubiquitination assay in BRCA1-deficient cells","pmids":["15965487"],"confidence":"Medium","gaps":["Ubiquitin chain type and lysine sites on TopoIIα not mapped","Single lab"]},{"year":2004,"claim":"Revealed a damage-responsive layer of BRCA1 regulation by showing p53- and CRM1-dependent nuclear export after IR, adding spatial control to its activity.","evidence":"Subcellular fractionation, leptomycin B, HPV E6 p53 inactivation, inducible p53 system","pmids":["15087457"],"confidence":"Medium","gaps":["Functional purpose of damage-induced export unresolved","Export signal within BRCA1 not mapped"]},{"year":2007,"claim":"Built the BRCA1-A complex by identifying Abraxas/CCDC98 as the adaptor linking BRCA1 to RAP80, explaining how BRCA1 foci form and how the G2/M checkpoint is enforced.","evidence":"Reciprocal Co-IP, siRNA knockdown, foci analysis, checkpoint assay","pmids":["17643121"],"confidence":"Medium","gaps":["Stoichiometry and full subunit architecture not resolved here","Single lab"]},{"year":2008,"claim":"Established BRCA1 as a sequence-specific transcriptional activator beyond its own locus, showing it drives SIRT1 expression to suppress Survivin via histone modification.","evidence":"ChIP, promoter reporter, siRNA epistasis, mouse tumor model","pmids":["18851829"],"confidence":"Medium","gaps":["Direct DNA-binding vs. cofactor recruitment at SIRT1 promoter unresolved","Single lab"]},{"year":2009,"claim":"Defined antagonistic and assembly regulation of the ligase: BAP1 inhibits BRCA1/BARD1 ubiquitination by both catalytic and non-catalytic means, and MERIT40 stabilizes the five-subunit BRCA1-A complex at breaks.","evidence":"Co-IP, surface plasmon resonance, in vitro ubiquitination with C91S mutant, foci and checkpoint assays","pmids":["19117993","19261748"],"confidence":"High","gaps":["In vivo significance of BAP1 inhibition for tumor suppression not established here","MERIT40 dependence in other BRCA1 complexes unaddressed"]},{"year":2009,"claim":"Connected BRCA1 ligase activity to hormone signaling by showing it monoubiquitinates and represses estrogen receptor-α, with a ligase-dead I26A mutant losing this function.","evidence":"In vitro ubiquitination and acetylation assays, I26A and C61G mutants, siRNA knockdown","pmids":["19887647"],"confidence":"Medium","gaps":["In vivo contribution to estrogen-driven tumorigenesis not measured here","Single lab"]},{"year":2010,"claim":"Defined an autoregulatory transcriptional loop: BRCA1 represses its own promoter in a BRCA1/E2F1/Rb complex that is disassembled by genotoxic stress to upregulate BRCA1.","evidence":"Tandem/sequential ChIP, promoter reporter, BRCA1 knockdown and overexpression","pmids":["20068145"],"confidence":"Medium","gaps":["Signal that dissolves the complex not identified","Single lab"]},{"year":2020,"claim":"Resolved how a single protein executes two opposing HR steps by demonstrating RNF168 redundancy with BRCA1 in PALB2 loading and defining separation-of-function alleles for resection (coiled-coil) versus RAD51 loading (Δ11).","evidence":"Compound mutant and double/triple knockout mouse genetics, RAD51 foci, PARP inhibitor sensitivity, forced PALB2 targeting","pmids":["30704900","32359443"],"confidence":"High","gaps":["Molecular basis of coiled-coil counteraction of Shieldin not structurally defined","How RNF168 substitutes for BRCA1 at the PALB2 step mechanistically unresolved"]},{"year":2021,"claim":"Provided the structural mechanism of BRCA1/BARD1 nucleosome recognition and ubiquitin transfer, explaining how the heterodimer reads the H2A K13/K15 DSB mark and writes C-terminal H2A ubiquitin to oppose 53BP1.","evidence":"Cryo-EM of BRCA1-BARD1–nucleosome complex, in vitro ubiquitylation, structure-guided mutagenesis","pmids":["34321665"],"confidence":"High","gaps":["Structural basis for substrate selectivity among other BRCA1 targets not addressed","How this activity integrates with full BRCA1-A complex unresolved"]},{"year":2021,"claim":"Identified upstream regulation of heterodimer assembly via SIRT2 deacetylation of the BARD1 RING interface and extended BRCA1 function to centromere protection through R-loop resolution at α-satellite repeats.","evidence":"Co-IP and deacetylation assays with SIRT2 depletion (HR/foci readouts); ChIP, DRIP, micronuclei scoring and Rad52 epistasis for centromeres","pmids":["33789098","34599155"],"confidence":"Medium","gaps":["Whether SIRT2 regulation operates in vivo during tumorigenesis unknown","Mechanism by which BRCA1 resolves centromeric R-loops not defined"]},{"year":2024,"claim":"Linked BRCA1 transcriptional control to ferroptosis vulnerability, showing it activates VDAC3 and GPX4 and that BRCA1 deficiency creates a GPX4-inhibitor and PARPi synergy via NCOA4-mediated ferritinophagy.","evidence":"Reporter assays, ChIP, viability assays with GPX4i/PARPi, NCOA4 knockdown, xenografts","pmids":["38552003"],"confidence":"Medium","gaps":["Direct vs. indirect transcriptional control of VDAC3/GPX4 not fully resolved","Single lab"]},{"year":null,"claim":"How BRCA1's many activities—HR, transcription, ubiquitin ligation toward diverse substrates, R-loop resolution, and chromatin maintenance—are coordinated within distinct complexes and which are most critical for tumor suppression remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking ligase activity to HR in vivo","Relative tumor-suppressive weight of transcriptional vs. repair functions undefined","Substrate selectivity rules for BRCA1/BARD1 unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[3,5,9,11,15]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,11,15]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,12,21]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[8,12,15]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,6,20]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[2,15,17]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[6,7]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,13,14,15]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,10,5]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,11,12,21]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,15,17]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,20]}],"complexes":["BRCA1-BARD1 heterodimer","BRCA1-A complex (RAP80/Abraxas/MERIT40/BRCC45)","BRCA1/E2F1/Rb repressive complex"],"partners":["BARD1","ATR","RAP80","CCDC98","MERIT40","BAP1","SIRT2","PALB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P38398","full_name":"Breast cancer type 1 susceptibility protein","aliases":["RING finger protein 53","RING-type E3 ubiquitin transferase BRCA1"],"length_aa":1863,"mass_kda":207.7,"function":"E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage (PubMed:10500182, PubMed:12887909, PubMed:12890688, PubMed:14976165, PubMed:16818604, PubMed:17525340, PubMed:19261748). It is unclear whether it also mediates the formation of other types of polyubiquitin chains (PubMed:12890688). The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability (PubMed:12890688, PubMed:14976165, PubMed:20351172). Regulates centrosomal microtubule nucleation (PubMed:18056443). Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle (PubMed:10724175, PubMed:11836499, PubMed:12183412, PubMed:19261748). Required for FANCD2 targeting to sites of DNA damage (PubMed:12887909). Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation (PubMed:16326698). Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks (PubMed:19369211). Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8 (PubMed:16818604). Acts as a transcriptional activator (PubMed:20160719)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P38398/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BRCA1","classification":"Common Essential","n_dependent_lines":611,"n_total_lines":1208,"dependency_fraction":0.5057947019867549},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"RPS6KA4","stoichiometry":0.2},{"gene":"VCL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BRCA1","total_profiled":1310},"omim":[{"mim_id":"621363","title":"MAP7 DOMAIN-CONTAINING PROTEIN 1; MAP7D1","url":"https://www.omim.org/entry/621363"},{"mim_id":"621279","title":"LONG INTERGENIC NON-PROTEIN CODING RNA 1011; LINC01011","url":"https://www.omim.org/entry/621279"},{"mim_id":"620693","title":"ASTEROID HOMOLOG 1; ASTE1","url":"https://www.omim.org/entry/620693"},{"mim_id":"620442","title":"BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 5; BROVCA5","url":"https://www.omim.org/entry/620442"},{"mim_id":"619762","title":"KURY-ISIDOR SYNDROME; KURIS","url":"https://www.omim.org/entry/619762"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRCA1"},"hgnc":{"alias_symbol":["RNF53","BRCC1","PPP1R53","FANCS"],"prev_symbol":[]},"alphafold":{"accession":"P38398","domains":[{"cath_id":"3.30.40.10","chopping":"4-98","consensus_level":"high","plddt":85.5901,"start":4,"end":98},{"cath_id":"3.40.50.10190","chopping":"1650-1758","consensus_level":"medium","plddt":94.5132,"start":1650,"end":1758},{"cath_id":"3.40.50.10190","chopping":"1759-1863","consensus_level":"medium","plddt":87.8605,"start":1759,"end":1863}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P38398","model_url":"https://alphafold.ebi.ac.uk/files/AF-P38398-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P38398-F1-predicted_aligned_error_v6.png","plddt_mean":41.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRCA1","jax_strain_url":"https://www.jax.org/strain/search?query=BRCA1"},"sequence":{"accession":"P38398","fasta_url":"https://rest.uniprot.org/uniprotkb/P38398.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P38398/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P38398"}},"corpus_meta":[{"pmid":"11832208","id":"PMC_11832208","title":"Cancer susceptibility and the functions of BRCA1 and BRCA2.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11832208","citation_count":1340,"is_preprint":false},{"pmid":"34081848","id":"PMC_34081848","title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.","date":"2021","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34081848","citation_count":1266,"is_preprint":false},{"pmid":"10549283","id":"PMC_10549283","title":"Brca1 controls homology-directed DNA repair.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10549283","citation_count":1021,"is_preprint":false},{"pmid":"15343273","id":"PMC_15343273","title":"BRCA1 and BRCA2: 1994 and beyond.","date":"2004","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15343273","citation_count":692,"is_preprint":false},{"pmid":"11114888","id":"PMC_11114888","title":"Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.","date":"2000","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11114888","citation_count":410,"is_preprint":false},{"pmid":"20029420","id":"PMC_20029420","title":"BRCA1 and its toolbox for the maintenance of genome integrity.","date":"2009","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20029420","citation_count":401,"is_preprint":false},{"pmid":"18851829","id":"PMC_18851829","title":"Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18851829","citation_count":289,"is_preprint":false},{"pmid":"12698198","id":"PMC_12698198","title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12698198","citation_count":283,"is_preprint":false},{"pmid":"10918303","id":"PMC_10918303","title":"Roles of BRCA1 and its interacting proteins.","date":"2000","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10918303","citation_count":257,"is_preprint":false},{"pmid":"10652533","id":"PMC_10652533","title":"Insights into the functions of BRCA1 and BRCA2.","date":"2000","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/10652533","citation_count":252,"is_preprint":false},{"pmid":"12419249","id":"PMC_12419249","title":"BRCA1 supports XIST RNA concentration on the inactive X chromosome.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12419249","citation_count":230,"is_preprint":false},{"pmid":"24675954","id":"PMC_24675954","title":"Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.","date":"2014","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24675954","citation_count":215,"is_preprint":false},{"pmid":"12767038","id":"PMC_12767038","title":"BRCA1 gene in breast cancer.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12767038","citation_count":208,"is_preprint":false},{"pmid":"7606717","id":"PMC_7606717","title":"Mutation analysis of the BRCA1 gene in ovarian cancers.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7606717","citation_count":205,"is_preprint":false},{"pmid":"19117993","id":"PMC_19117993","title":"BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19117993","citation_count":180,"is_preprint":false},{"pmid":"19383375","id":"PMC_19383375","title":"The contribution of BRCA1 and BRCA2 to ovarian cancer.","date":"2009","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383375","citation_count":174,"is_preprint":false},{"pmid":"21203981","id":"PMC_21203981","title":"The role of BRCA1 in DNA damage response.","date":"2010","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/21203981","citation_count":173,"is_preprint":false},{"pmid":"25348513","id":"PMC_25348513","title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25348513","citation_count":156,"is_preprint":false},{"pmid":"32877777","id":"PMC_32877777","title":"BAP1: Not just a BRCA1-associated protein.","date":"2020","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32877777","citation_count":144,"is_preprint":false},{"pmid":"27241552","id":"PMC_27241552","title":"RANKL/RANK control Brca1 mutation- .","date":"2016","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27241552","citation_count":139,"is_preprint":false},{"pmid":"9261099","id":"PMC_9261099","title":"Complex regulation of the BRCA1 gene.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9261099","citation_count":134,"is_preprint":false},{"pmid":"11156530","id":"PMC_11156530","title":"Lessons learned from BRCA1 and BRCA2.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11156530","citation_count":133,"is_preprint":false},{"pmid":"19261748","id":"PMC_19261748","title":"MERIT40 facilitates BRCA1 localization and DNA damage repair.","date":"2009","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/19261748","citation_count":132,"is_preprint":false},{"pmid":"17643121","id":"PMC_17643121","title":"CCDC98 targets BRCA1 to DNA damage sites.","date":"2007","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17643121","citation_count":129,"is_preprint":false},{"pmid":"26412854","id":"PMC_26412854","title":"A BRCA1-interacting lncRNA regulates homologous recombination.","date":"2015","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26412854","citation_count":128,"is_preprint":false},{"pmid":"19887647","id":"PMC_19887647","title":"BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19887647","citation_count":123,"is_preprint":false},{"pmid":"22843421","id":"PMC_22843421","title":"Mechanisms of BRCA1 tumor suppression.","date":"2012","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22843421","citation_count":114,"is_preprint":false},{"pmid":"34321665","id":"PMC_34321665","title":"Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34321665","citation_count":113,"is_preprint":false},{"pmid":"12887909","id":"PMC_12887909","title":"BRCA1-independent ubiquitination of FANCD2.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12887909","citation_count":112,"is_preprint":false},{"pmid":"12890739","id":"PMC_12890739","title":"Emerging roles of BRCA1 alternative splicing.","date":"2003","source":"Molecular pathology : MP","url":"https://pubmed.ncbi.nlm.nih.gov/12890739","citation_count":112,"is_preprint":false},{"pmid":"16633366","id":"PMC_16633366","title":"Is there more to BARD1 than BRCA1?","date":"2006","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16633366","citation_count":99,"is_preprint":false},{"pmid":"12214252","id":"PMC_12214252","title":"Roles of BRCA1 in centrosome duplication.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12214252","citation_count":99,"is_preprint":false},{"pmid":"30704900","id":"PMC_30704900","title":"BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30704900","citation_count":96,"is_preprint":false},{"pmid":"15965487","id":"PMC_15965487","title":"BRCA1 participates in DNA decatenation.","date":"2005","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15965487","citation_count":95,"is_preprint":false},{"pmid":"22836122","id":"PMC_22836122","title":"Links between genome integrity and BRCA1 tumor suppression.","date":"2012","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22836122","citation_count":91,"is_preprint":false},{"pmid":"11016617","id":"PMC_11016617","title":"Estrogens, BRCA1, and breast cancer.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11016617","citation_count":86,"is_preprint":false},{"pmid":"26873923","id":"PMC_26873923","title":"Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26873923","citation_count":84,"is_preprint":false},{"pmid":"15975711","id":"PMC_15975711","title":"BRCA1 regulation of transcription.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15975711","citation_count":82,"is_preprint":false},{"pmid":"32719340","id":"PMC_32719340","title":"Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32719340","citation_count":81,"is_preprint":false},{"pmid":"28884397","id":"PMC_28884397","title":"BRCA1 gene: function and deficiency.","date":"2017","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28884397","citation_count":77,"is_preprint":false},{"pmid":"24639535","id":"PMC_24639535","title":"Role of BRCA1 in brain development.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24639535","citation_count":76,"is_preprint":false},{"pmid":"23620175","id":"PMC_23620175","title":"In brief: BRCA1 and BRCA2.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23620175","citation_count":73,"is_preprint":false},{"pmid":"26048987","id":"PMC_26048987","title":"Deciphering the BRCA1 Tumor Suppressor Network.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26048987","citation_count":72,"is_preprint":false},{"pmid":"11156529","id":"PMC_11156529","title":"BRCA1 and cell signaling.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11156529","citation_count":71,"is_preprint":false},{"pmid":"16530420","id":"PMC_16530420","title":"Histopathology of BRCA1- and BRCA2-associated breast cancer.","date":"2006","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16530420","citation_count":68,"is_preprint":false},{"pmid":"16172191","id":"PMC_16172191","title":"BRCA1 in hormonal carcinogenesis: basic and clinical research.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16172191","citation_count":65,"is_preprint":false},{"pmid":"14506230","id":"PMC_14506230","title":"BRCA1 associates with processive RNA polymerase II.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14506230","citation_count":63,"is_preprint":false},{"pmid":"10528224","id":"PMC_10528224","title":"Emerging roles of BRCA1 in transcriptional regulation and DNA repair.","date":"1999","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10528224","citation_count":62,"is_preprint":false},{"pmid":"16108063","id":"PMC_16108063","title":"Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking.","date":"2005","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16108063","citation_count":62,"is_preprint":false},{"pmid":"20068145","id":"PMC_20068145","title":"Transcriptional autoregulation by BRCA1.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20068145","citation_count":59,"is_preprint":false},{"pmid":"15087457","id":"PMC_15087457","title":"DNA damage induces p53-dependent BRCA1 nuclear export.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15087457","citation_count":59,"is_preprint":false},{"pmid":"10480351","id":"PMC_10480351","title":"BRCA1 mutations in African Americans.","date":"1999","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10480351","citation_count":57,"is_preprint":false},{"pmid":"10597248","id":"PMC_10597248","title":"Regulation of BRCA1 by protein degradation.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597248","citation_count":57,"is_preprint":false},{"pmid":"7987831","id":"PMC_7987831","title":"The search for BRCA1.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7987831","citation_count":56,"is_preprint":false},{"pmid":"12647291","id":"PMC_12647291","title":"Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair--perhaps through transcription.","date":"2003","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12647291","citation_count":56,"is_preprint":false},{"pmid":"10945975","id":"PMC_10945975","title":"BRCA1 physically and functionally interacts with ATF1.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10945975","citation_count":56,"is_preprint":false},{"pmid":"15569676","id":"PMC_15569676","title":"The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15569676","citation_count":56,"is_preprint":false},{"pmid":"10580847","id":"PMC_10580847","title":"Is TP53 dysfunction required for BRCA1-associated carcinogenesis?","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10580847","citation_count":55,"is_preprint":false},{"pmid":"19223511","id":"PMC_19223511","title":"The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19223511","citation_count":55,"is_preprint":false},{"pmid":"12957814","id":"PMC_12957814","title":"BRCA1 in cancer, cell cycle and genomic stability.","date":"2003","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/12957814","citation_count":53,"is_preprint":false},{"pmid":"10369075","id":"PMC_10369075","title":"BRCA1 and BRCA2 in breast cancer.","date":"1999","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/10369075","citation_count":52,"is_preprint":false},{"pmid":"23802008","id":"PMC_23802008","title":"BRCA1 in the DNA damage response and at telomeres.","date":"2013","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23802008","citation_count":51,"is_preprint":false},{"pmid":"10195418","id":"PMC_10195418","title":"The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.","date":"1999","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10195418","citation_count":48,"is_preprint":false},{"pmid":"30804228","id":"PMC_30804228","title":"Synergistic lethality between BRCA1 and H3K9me2 loss reflects satellite derepression.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30804228","citation_count":48,"is_preprint":false},{"pmid":"24704793","id":"PMC_24704793","title":"BRCA1 and Oxidative Stress.","date":"2014","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/24704793","citation_count":47,"is_preprint":false},{"pmid":"10085126","id":"PMC_10085126","title":"Positive regulation of the BRCA1 promoter.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10085126","citation_count":47,"is_preprint":false},{"pmid":"8695765","id":"PMC_8695765","title":"Mutations of the BRCA1 gene in human cancer.","date":"1996","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/8695765","citation_count":46,"is_preprint":false},{"pmid":"16978908","id":"PMC_16978908","title":"Functional assays for BRCA1 and BRCA2.","date":"2006","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16978908","citation_count":45,"is_preprint":false},{"pmid":"38552003","id":"PMC_38552003","title":"BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38552003","citation_count":44,"is_preprint":false},{"pmid":"32359443","id":"PMC_32359443","title":"BRCA1 Mutational Complementation Induces Synthetic Viability.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32359443","citation_count":44,"is_preprint":false},{"pmid":"26383678","id":"PMC_26383678","title":"BRCA1 Mutation: A Predictive Marker for Radiation Therapy?","date":"2015","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/26383678","citation_count":44,"is_preprint":false},{"pmid":"36914836","id":"PMC_36914836","title":"Preneoplastic stromal cells promote BRCA1-mediated breast tumorigenesis.","date":"2023","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36914836","citation_count":43,"is_preprint":false},{"pmid":"34599155","id":"PMC_34599155","title":"BRCA1 prevents R-loop-associated centromeric instability.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34599155","citation_count":43,"is_preprint":false},{"pmid":"34591954","id":"PMC_34591954","title":"The BRCA1/BARD1 ubiquitin ligase and its substrates.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34591954","citation_count":42,"is_preprint":false},{"pmid":"13679996","id":"PMC_13679996","title":"BRCA1 and p53: compensatory roles in DNA repair.","date":"2003","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/13679996","citation_count":41,"is_preprint":false},{"pmid":"31552267","id":"PMC_31552267","title":"Moving Mountains-The BRCA1 Promotion of DNA Resection.","date":"2019","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31552267","citation_count":41,"is_preprint":false},{"pmid":"20608970","id":"PMC_20608970","title":"BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20608970","citation_count":39,"is_preprint":false},{"pmid":"24131965","id":"PMC_24131965","title":"BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.","date":"2013","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24131965","citation_count":39,"is_preprint":false},{"pmid":"16721040","id":"PMC_16721040","title":"BRCA1 phosphorylation: biological consequences.","date":"2006","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16721040","citation_count":39,"is_preprint":false},{"pmid":"10403822","id":"PMC_10403822","title":"Casein kinase 2 binds to and phosphorylates BRCA1.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10403822","citation_count":39,"is_preprint":false},{"pmid":"11405179","id":"PMC_11405179","title":"BRCA1 and prostate cancer.","date":"2001","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11405179","citation_count":38,"is_preprint":false},{"pmid":"16861894","id":"PMC_16861894","title":"BRCA1-mediated ubiquitylation.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16861894","citation_count":36,"is_preprint":false},{"pmid":"29511213","id":"PMC_29511213","title":"Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29511213","citation_count":36,"is_preprint":false},{"pmid":"16357529","id":"PMC_16357529","title":"Assessing the link between BACH1 and BRCA1 in the FA pathway.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16357529","citation_count":36,"is_preprint":false},{"pmid":"27325824","id":"PMC_27325824","title":"Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage.","date":"2016","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27325824","citation_count":36,"is_preprint":false},{"pmid":"25260588","id":"PMC_25260588","title":"A portable BRCA1-HAC (human artificial chromosome) module for analysis of BRCA1 tumor suppressor function.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25260588","citation_count":36,"is_preprint":false},{"pmid":"9553742","id":"PMC_9553742","title":"BRCA1: a review of structure and putative functions.","date":"1998","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/9553742","citation_count":35,"is_preprint":false},{"pmid":"20608971","id":"PMC_20608971","title":"BRCA1 16 years later: DNA damage-induced BRCA1 shuttling.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20608971","citation_count":35,"is_preprint":false},{"pmid":"11170347","id":"PMC_11170347","title":"Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice.","date":"2001","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/11170347","citation_count":35,"is_preprint":false},{"pmid":"19445691","id":"PMC_19445691","title":"Aromatase expression is increased in BRCA1 mutation carriers.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19445691","citation_count":34,"is_preprint":false},{"pmid":"28104682","id":"PMC_28104682","title":"Out-RANKing BRCA1 in Mutation Carriers.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28104682","citation_count":33,"is_preprint":false},{"pmid":"33789098","id":"PMC_33789098","title":"SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33789098","citation_count":33,"is_preprint":false},{"pmid":"17993233","id":"PMC_17993233","title":"p53, BRCA1 and breast Cancer chemoresistance.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17993233","citation_count":32,"is_preprint":false},{"pmid":"23447579","id":"PMC_23447579","title":"TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23447579","citation_count":32,"is_preprint":false},{"pmid":"12496474","id":"PMC_12496474","title":"Transactivation of repair genes by BRCA1.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12496474","citation_count":32,"is_preprint":false},{"pmid":"15065664","id":"PMC_15065664","title":"Association of BRCA1 with the inactive X chromosome and XIST RNA.","date":"2004","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15065664","citation_count":31,"is_preprint":false},{"pmid":"37587346","id":"PMC_37587346","title":"Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37587346","citation_count":30,"is_preprint":false},{"pmid":"15254424","id":"PMC_15254424","title":"Understanding germ-line mutations in BRCA1.","date":"2004","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15254424","citation_count":30,"is_preprint":false},{"pmid":"15254397","id":"PMC_15254397","title":"BRCA1 and transcription.","date":"2004","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15254397","citation_count":29,"is_preprint":false},{"pmid":"35432218","id":"PMC_35432218","title":"BRCA1: An Endocrine and Metabolic Regulator.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35432218","citation_count":29,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39494,"output_tokens":5793,"usd":0.102689,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14369,"output_tokens":5666,"usd":0.106747,"stage2_stop_reason":"end_turn"},"total_usd":0.209436,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Brca1-deficient mouse embryonic stem cells have impaired repair of chromosomal DNA double-strand breaks (DSBs) by homologous recombination, with altered relative frequencies of homologous vs. nonhomologous DNA integration and DSB repair, demonstrating a caretaker role for BRCA1 in promoting homologous recombination and limiting mutagenic nonhomologous repair.\",\n      \"method\": \"Genetic knockout in mouse embryonic stem cells with DSB repair frequency assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype (HR frequency measurement), replicated conceptually across multiple labs\",\n      \"pmids\": [\"10549283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ATR phosphorylates BRCA1 on six Ser/Thr residues including Ser1423 in vitro and in vivo in response to UV light, hydroxyurea, aphidicolin, and partially in response to ionizing radiation. ATR and BRCA1 co-localize in nuclear foci at stalled replication forks, placing them in the same genotoxic stress-responsive pathway.\",\n      \"method\": \"In vitro kinase assay, kinase-inactive ATR dominant-negative expression, immunofluorescence co-localization of nuclear foci\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro phosphorylation assay plus dominant-negative in-cell validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"11114888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRCA1 colocalizes with markers of the inactive X chromosome (Xi) in female somatic cells and physically associates with XIST RNA as detected by chromatin immunoprecipitation. BRCA1-deficient cells show defects in Xi chromatin structure and XIST RNA concentration; reconstitution of BRCA1-deficient cells with wild-type BRCA1 restored focal XIST RNA staining and reduced re-expression of a silenced Xi-located GFP transgene.\",\n      \"method\": \"Chromatin immunoprecipitation, immunofluorescence, BRCA1 reconstitution in deficient cells, GFP reporter assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reconstitution experiment, and functional reporter assay in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"12419249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The purified BRCA1/BARD1 complex, together with E1 and UbcH5a, is sufficient to reconstitute monoubiquitination of FANCD2 in vitro. However, siRNA-mediated knockdown of BRCA1 in human cells does not lead to a defect in FANCD2 ubiquitination, and ablation of RING finger domains of BRCA1 or BARD1 in DT40 cells leaves FANCD2 modification intact. BRCA1 affects accumulation of FANCD2 at DNA damage sites but BRCA1/BARD1 E3 ligase activity is not essential for FANCD2 monoubiquitination in vivo.\",\n      \"method\": \"In vitro ubiquitination reconstitution, siRNA knockdown, RING domain ablation in DT40 cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution plus genetic ablation in cells, two orthogonal methods establishing a negative result in vivo\",\n      \"pmids\": [\"12887909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BRCA1 interacts with processive (hyperphosphorylated, IIO form) RNA polymerase II rather than the hypophosphorylated promoter-associated form (IIA) in undamaged cells. BRCA1-RNA pol II complexes are highly functional in transcriptional run-off assays and the interaction is disrupted by DNA-damaging agents.\",\n      \"method\": \"Fractionation, co-immunoprecipitation, transcriptional run-off assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with functional run-off assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"14506230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRCA1 interacts and colocalizes with topoisomerase IIα in S-phase cells. BRCA1-deficient cells show lagging chromosomes and defective DNA decatenation in vitro, phenocopying topoisomerase IIα inhibition. Topoisomerase IIα is ubiquitinated in a BRCA1-dependent manner, and its ubiquitination correlates with higher DNA decatenation activity.\",\n      \"method\": \"Co-immunoprecipitation, co-localization, in vitro decatenation assay, ubiquitination assay in BRCA1-deficient cells\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vitro functional assay and ubiquitination assay, single lab\",\n      \"pmids\": [\"15965487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRCA1 RING and BRCT domains cooperate to target BRCA1 to ionizing radiation-induced nuclear foci. Cancer mutations in the BRCT domain abolish recruitment. A RING-BRCT fusion restores foci targeting, co-localizes with MDC1, and inhibits entry of endogenous BRCA1 into foci. Neither RING nor BRCT domain alone is sufficient for targeting.\",\n      \"method\": \"YFP-tagged domain mapping, live-cell fluorescence imaging, ionizing radiation treatment, co-localization with MDC1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct imaging of tagged BRCA1 fragments with cancer mutation controls, single lab\",\n      \"pmids\": [\"15569676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCDC98 (Abraxas) is a component of the BRCA1-RAP80 complex that mediates BRCA1's association with RAP80, controls DNA damage-induced formation of BRCA1 foci, and is required for BRCA1-dependent G2/M checkpoint activation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci analysis, checkpoint assay\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional checkpoint assay, single lab\",\n      \"pmids\": [\"17643121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRCA1 binds the SIRT1 promoter and increases SIRT1 expression, which in turn inhibits Survivin by altering epigenetic modification of histone H3. Absence of SIRT1 blocks BRCA1's regulation of Survivin.\",\n      \"method\": \"Chromatin immunoprecipitation, promoter reporter assay, siRNA knockdown, Western blot, mouse tumor model\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP at SIRT1 promoter plus epistasis knockdown experiment, single lab\",\n      \"pmids\": [\"18851829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCA1-associated protein 1 (BAP1) interacts with the RING finger domain of BARD1 and interferes with the BRCA1/BARD1 E3 ligase association via surface plasmon resonance. BAP1 inhibits BRCA1 autoubiquitination and NPM1/B23 ubiquitination by BRCA1/BARD1. A catalytically inactive BAP1 mutant (C91S) still inhibits ubiquitination, indicating a second non-catalytic inhibitory mechanism.\",\n      \"method\": \"Co-immunoprecipitation, BIAcore surface plasmon resonance, in vitro ubiquitination assay, catalytically inactive mutant (C91S), shRNA knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of ubiquitination with mutagenesis (C91S) and biophysical binding assay, multiple orthogonal methods in one study\",\n      \"pmids\": [\"19117993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MERIT40 (a 40 kDa protein) assembles into the RAP80/CCDC98-containing BRCA1-A complex via direct interaction with BRE/BRCC45, and is required for maintaining stability of BRE and the five-subunit complex at DNA damage sites, thereby regulating BRCA1 retention at DNA breaks and checkpoint function.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, immunofluorescence foci analysis, checkpoint assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional foci and checkpoint assays, single lab\",\n      \"pmids\": [\"19261748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCA1 overexpression reduces acetylation of estrogen receptor-α (ER-α) and increases mono-ubiquitination of ER-α; a BRCA1 mutant defective for ubiquitin ligase activity (I26A) failed to ubiquitinate ER-α or repress its transcriptional activity in vivo. Wild-type BRCA1 but not cancer mutant C61G inhibited p300-mediated acetylation of ER-α in vitro.\",\n      \"method\": \"In vitro ubiquitination assay, in vitro acetylation assay, siRNA knockdown, overexpression of BRCA1 ubiquitin-ligase-dead mutant (I26A), Western blot\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro assay plus active-site mutant (I26A), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19887647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCA1 assembles with complexes containing E2F-1 and RB to form a repressive multicomponent transcriptional complex that inhibits BRCA1 promoter transcription (autoregulatory loop). Genotoxic stress disrupts this complex, displacing BRCA1 from its own promoter and upregulating BRCA1 transcription. Tandem ChIP confirmed the BRCA1/E2F1/Rb complex at the BRCA1 promoter in vivo.\",\n      \"method\": \"Chromatin immunoprecipitation (sequential/tandem ChIP), promoter-reporter assay, BRCA1 knockdown and overexpression\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tandem ChIP plus functional reporter and BRCA1 depletion/overexpression, single lab\",\n      \"pmids\": [\"20068145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RNF168 acts redundantly with BRCA1 to load PALB2 onto damaged DNA. Loss of RNF168 negates synthetic rescue of BRCA1 deficiency by 53BP1 deletion. Forced targeting of PALB2 to DNA breaks circumvents BRCA1 haploinsufficiency. BRCA1 promotes two distinct steps of homologous recombination: DNA end resection (counteracting 53BP1) and RAD51 loading (via PALB2 recruitment).\",\n      \"method\": \"Genetic epistasis (double and triple KO mice), RAD51 foci assay, PARP inhibitor sensitivity, forced PALB2 targeting\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis in mouse models plus cell-based RAD51 foci and PARP inhibitor assays, multiple orthogonal methods\",\n      \"pmids\": [\"30704900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRCA1 promotes two genetically separable activities in homologous recombination: (1) counteracting 53BP1-RIF1-Shieldin to promote DNA end resection (via the coiled-coil domain) and (2) promoting RAD51 loading (via the Δ11 region). Brca1CC and Brca1Δ11 alleles are separation-of-function mutations that complement each other to provide sufficient HR for normal development.\",\n      \"method\": \"Mouse genetics (Brca1CC/Δ11 compound heterozygotes), HR assays, RAD51 foci, 53BP1-RIF1 epistasis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with separation-of-function alleles in mice, multiple functional readouts, rigorous controls\",\n      \"pmids\": [\"32359443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of BRCA1-BARD1 bound to nucleosome revealed that ankyrin repeat and tandem BRCT domains in BARD1 bind nucleosomal histones, DNA, and monoubiquitin on H2A K13/K15 (DSB-specific marks). RING domains in BRCA1-BARD1 orient an E2 ubiquitin-conjugating enzyme atop the nucleosome for ubiquitin transfer to flexible C-terminal tails of H2A/H2AX. Recognition of N-terminal H2A monoubiquitin blocks polyubiquitin chain formation and cooperatively promotes C-terminal H2A ubiquitylation, opposing 53BP1.\",\n      \"method\": \"Cryo-electron microscopy, biochemical ubiquitylation assays, structure-guided mutational analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structure with functional validation by mutagenesis and in vitro ubiquitylation assays in one rigorous study\",\n      \"pmids\": [\"34321665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SIRT2 deacetylase complexes with BRCA1-BARD1 and deacetylates conserved lysines in the BARD1 RING domain at the BRCA1-BARD1 interface, promoting BRCA1-BARD1 heterodimerization, mutual stability, nuclear retention, localization to DNA damage sites, and efficient homologous recombination.\",\n      \"method\": \"Co-immunoprecipitation, deacetylation assay, SIRT2 knockdown/knockout, HR assay, immunofluorescence foci analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional HR and foci assays with deacetylation biochemistry, single lab\",\n      \"pmids\": [\"33789098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRCA1 associates with centromeric chromatin in an R-loop-dependent manner and counteracts accumulation of R-loops at centromeric α-satellite repeats. BRCA1-deficient cells show impaired CENP-A localization, increased centromeric RNA transcription, increased centromeric breakage, acentric micronuclei, and Rad52-dependent hyper-recombination at centromeric satellites, all R-loop-dependent.\",\n      \"method\": \"Chromatin immunoprecipitation, immunofluorescence, BRCA1 knockdown, R-loop detection (DRIP), micronuclei scoring, Rad52 epistasis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus KD with multiple functional readouts and epistasis, single lab\",\n      \"pmids\": [\"34599155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Casein kinase 2 (CK2) β-subunit associates with the carboxy-terminal region of BRCA1 (yeast two-hybrid and Sf9 cell confirmation) and phosphorylates BRCA1 in vitro at Ser1572; the cancer-associated missense mutation M1775R in BRCA1 weakens the CK2β association.\",\n      \"method\": \"Yeast two-hybrid, in vitro kinase assay, site-directed mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, yeast two-hybrid plus in vitro kinase assay without in-cell validation\",\n      \"pmids\": [\"10403822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BRCA1 physically associates with ATF1 (a CREB/ATF transcription factor) via the BRCA1 RING finger domain in vitro, in yeast, and in human cells. BRCA1 stimulates transcription from a CRE reporter gene and from the TNF-α promoter in a CRE-dependent manner.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro binding, transient transfection reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, yeast two-hybrid and Co-IP plus reporter assay, no mutagenesis confirming RING-ATF1 interface in cells\",\n      \"pmids\": [\"10945975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DNA damage (ionizing radiation) induces BRCA1 nuclear export in a dose-dependent, CRM1-dependent manner that also requires wild-type p53 function. BRCA1 nuclear export occurs across all cell cycle phases, representing a p53-dependent regulatory mechanism of BRCA1 localization in response to DNA damage.\",\n      \"method\": \"Immunohistochemical staining, subcellular fractionation and Western blot, CRM1 inhibitor (leptomycin B), p53 inactivation by HPV E6, tetracycline-inducible p53 system\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation with functional inhibitors and two independent cell systems, single lab\",\n      \"pmids\": [\"15087457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCA1 promotes transcription of both VDAC3 and GPX4; BRCA1 deficiency blocks VDAC3-dependent erastin-induced ferroptosis but sensitizes cells to GPX4 inhibitor-induced ferroptosis. NCOA4-mediated ferritinophagy and defective GPX4 induction synergize PARPi and GPX4 inhibition to induce ferroptosis in BRCA1-deficient cancer cells.\",\n      \"method\": \"Transcriptional reporter assay, ChIP, cell viability assays with GPX4i and PARPi, NCOA4 knockdown, xenograft models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional ferroptosis assays with multiple inhibitors and in vivo xenograft model, single lab\",\n      \"pmids\": [\"38552003\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRCA1 is a multifunctional nuclear tumor suppressor that forms a RING-domain E3 ubiquitin ligase heterodimer with BARD1 (whose nucleosome-recognition and ubiquitylation mechanism has been resolved by cryo-EM) and assembles into distinct protein complexes—including the RAP80/Abraxas/MERIT40-containing BRCA1-A complex—that are recruited to DNA double-strand breaks marked by H2A-K13/K15 monoubiquitin; at breaks, BRCA1 promotes homologous recombination through two separable activities—counteracting 53BP1-RIF1-Shieldin to enable DNA end resection, and collaborating with RNF168 to load PALB2/BRCA2/RAD51—while also being phosphorylated by ATM and ATR at multiple sites (including Ser1423) to coordinate checkpoint signaling, ubiquitylating substrates such as topoisomerase IIα and ER-α to regulate DNA decatenation and hormone receptor activity respectively, maintaining centromere stability by resolving R-loops at α-satellite repeats, supporting XIST RNA concentration on the inactive X chromosome, and autoregulating its own transcription through a repressive BRCA1/E2F1/Rb complex that is dissolved upon genotoxic stress.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRCA1 is a multifunctional nuclear tumor suppressor that safeguards genome integrity by promoting error-free homologous recombination (HR) repair of DNA double-strand breaks and limiting mutagenic nonhomologous repair [#0]. It executes HR through two genetically separable activities: a coiled-coil-dependent function that counteracts the 53BP1-RIF1-Shieldin axis to license DNA end resection, and a \\u039411-region/PALB2-dependent function that loads RAD51 onto resected DNA, with RNF168 acting redundantly with BRCA1 in the PALB2-loading step [#13, #14]. BRCA1 functions as a RING-domain heterodimer with BARD1; cryo-EM of the BRCA1-BARD1\\u2013nucleosome complex shows BARD1 ankyrin and BRCT domains reading nucleosomal histones, DNA, and the DSB-specific H2A K13/K15 monoubiquitin mark while the RING domains position an E2 enzyme for C-terminal H2A ubiquitylation that opposes 53BP1 [#15]. Recruitment to ionizing-radiation-induced foci requires cooperation of the BRCA1 RING and BRCT domains and co-localization with MDC1, with cancer mutations abolishing targeting [#6], and BRCA1 retention at breaks is organized by the RAP80/Abraxas(CCDC98)/MERIT40-containing BRCA1-A complex, which controls foci formation and the G2/M checkpoint [#7, #10]. Heterodimer assembly and DNA-damage localization are tuned by SIRT2-mediated deacetylation of the BARD1 RING interface, while BAP1 antagonizes the BRCA1/BARD1 ligase through both catalytic and non-catalytic mechanisms [#16, #9]. As an E3 ubiquitin ligase BRCA1/BARD1 modifies substrates including topoisomerase II\\u03b1, regulating DNA decatenation and chromosome segregation [#5], and estrogen receptor-\\u03b1, repressing its transcriptional activity [#11]. BRCA1 activity is integrated into genotoxic stress signaling through ATR phosphorylation of multiple residues including Ser1423 at stalled replication forks [#1] and through p53/CRM1-dependent nuclear export after DNA damage [#20]. Beyond repair, BRCA1 maintains centromere stability by resolving R-loops at \\u03b1-satellite repeats to preserve CENP-A loading [#17], supports XIST RNA concentration and chromatin structure on the inactive X chromosome [#2], and acts as a transcriptional regulator\\u2014autorepressing its own promoter via a BRCA1/E2F1/Rb complex dissolved by genotoxic stress [#12] and controlling target genes such as SIRT1 and the ferroptosis regulators VDAC3 and GPX4 [#8, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established BRCA1's foundational caretaker role by showing it is required for accurate double-strand break repair rather than acting indirectly, defining the genome-stability function that frames all later mechanism.\",\n      \"evidence\": \"Brca1 knockout mouse embryonic stem cells with DSB repair frequency assays\",\n      \"pmids\": [\"10549283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the molecular partners executing HR\", \"Did not separate resection from RAD51-loading roles\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed BRCA1 downstream of replication-stress and damage signaling by identifying ATR as a kinase that phosphorylates it at defined residues, linking BRCA1 localization to the genotoxic checkpoint machinery.\",\n      \"evidence\": \"In vitro kinase assay, dominant-negative kinase-inactive ATR, foci co-localization at stalled forks\",\n      \"pmids\": [\"11114888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of each phosphosite not fully resolved\", \"Relationship to ATM-dependent sites not addressed here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended BRCA1 function beyond break repair to chromatin maintenance, showing it associates with XIST RNA and is needed for inactive-X chromatin integrity.\",\n      \"evidence\": \"ChIP, immunofluorescence, BRCA1 reconstitution, silenced GFP reporter on Xi\",\n      \"pmids\": [\"12419249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect role in XIST localization unresolved\", \"Mechanism connecting BRCA1 to XIST concentration unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Clarified the in vivo relevance of BRCA1/BARD1 E3 ligase activity by demonstrating that, despite reconstituting FANCD2 monoubiquitination in vitro, the ligase is dispensable for that modification in cells, tightening claims about its physiological substrates.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution, siRNA knockdown, RING ablation in DT40 cells\",\n      \"pmids\": [\"12887909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The bona fide essential in vivo substrates of BRCA1/BARD1 left undefined\", \"How BRCA1 affects FANCD2 accumulation at damage sites without ubiquitinating it unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the domain logic of BRCA1 recruitment, showing RING and BRCT domains must cooperate for foci targeting and that cancer mutations disrupt this, linking genotype to localization failure.\",\n      \"evidence\": \"YFP-tagged domain mapping, live-cell imaging after IR, MDC1 co-localization\",\n      \"pmids\": [\"15569676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ligand bound by the cooperating domains not defined here\", \"Single lab, imaging-based\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified topoisomerase II\\u03b1 as a BRCA1-dependent ubiquitination target and connected BRCA1 to chromosome segregation through DNA decatenation, broadening its mechanistic repertoire beyond HR.\",\n      \"evidence\": \"Co-IP, co-localization, in vitro decatenation assay, ubiquitination assay in BRCA1-deficient cells\",\n      \"pmids\": [\"15965487\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin chain type and lysine sites on TopoII\\u03b1 not mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed a damage-responsive layer of BRCA1 regulation by showing p53- and CRM1-dependent nuclear export after IR, adding spatial control to its activity.\",\n      \"evidence\": \"Subcellular fractionation, leptomycin B, HPV E6 p53 inactivation, inducible p53 system\",\n      \"pmids\": [\"15087457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional purpose of damage-induced export unresolved\", \"Export signal within BRCA1 not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Built the BRCA1-A complex by identifying Abraxas/CCDC98 as the adaptor linking BRCA1 to RAP80, explaining how BRCA1 foci form and how the G2/M checkpoint is enforced.\",\n      \"evidence\": \"Reciprocal Co-IP, siRNA knockdown, foci analysis, checkpoint assay\",\n      \"pmids\": [\"17643121\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and full subunit architecture not resolved here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established BRCA1 as a sequence-specific transcriptional activator beyond its own locus, showing it drives SIRT1 expression to suppress Survivin via histone modification.\",\n      \"evidence\": \"ChIP, promoter reporter, siRNA epistasis, mouse tumor model\",\n      \"pmids\": [\"18851829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA-binding vs. cofactor recruitment at SIRT1 promoter unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined antagonistic and assembly regulation of the ligase: BAP1 inhibits BRCA1/BARD1 ubiquitination by both catalytic and non-catalytic means, and MERIT40 stabilizes the five-subunit BRCA1-A complex at breaks.\",\n      \"evidence\": \"Co-IP, surface plasmon resonance, in vitro ubiquitination with C91S mutant, foci and checkpoint assays\",\n      \"pmids\": [\"19117993\", \"19261748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of BAP1 inhibition for tumor suppression not established here\", \"MERIT40 dependence in other BRCA1 complexes unaddressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected BRCA1 ligase activity to hormone signaling by showing it monoubiquitinates and represses estrogen receptor-\\u03b1, with a ligase-dead I26A mutant losing this function.\",\n      \"evidence\": \"In vitro ubiquitination and acetylation assays, I26A and C61G mutants, siRNA knockdown\",\n      \"pmids\": [\"19887647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo contribution to estrogen-driven tumorigenesis not measured here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined an autoregulatory transcriptional loop: BRCA1 represses its own promoter in a BRCA1/E2F1/Rb complex that is disassembled by genotoxic stress to upregulate BRCA1.\",\n      \"evidence\": \"Tandem/sequential ChIP, promoter reporter, BRCA1 knockdown and overexpression\",\n      \"pmids\": [\"20068145\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signal that dissolves the complex not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved how a single protein executes two opposing HR steps by demonstrating RNF168 redundancy with BRCA1 in PALB2 loading and defining separation-of-function alleles for resection (coiled-coil) versus RAD51 loading (\\u039411).\",\n      \"evidence\": \"Compound mutant and double/triple knockout mouse genetics, RAD51 foci, PARP inhibitor sensitivity, forced PALB2 targeting\",\n      \"pmids\": [\"30704900\", \"32359443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of coiled-coil counteraction of Shieldin not structurally defined\", \"How RNF168 substitutes for BRCA1 at the PALB2 step mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided the structural mechanism of BRCA1/BARD1 nucleosome recognition and ubiquitin transfer, explaining how the heterodimer reads the H2A K13/K15 DSB mark and writes C-terminal H2A ubiquitin to oppose 53BP1.\",\n      \"evidence\": \"Cryo-EM of BRCA1-BARD1\\u2013nucleosome complex, in vitro ubiquitylation, structure-guided mutagenesis\",\n      \"pmids\": [\"34321665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for substrate selectivity among other BRCA1 targets not addressed\", \"How this activity integrates with full BRCA1-A complex unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified upstream regulation of heterodimer assembly via SIRT2 deacetylation of the BARD1 RING interface and extended BRCA1 function to centromere protection through R-loop resolution at \\u03b1-satellite repeats.\",\n      \"evidence\": \"Co-IP and deacetylation assays with SIRT2 depletion (HR/foci readouts); ChIP, DRIP, micronuclei scoring and Rad52 epistasis for centromeres\",\n      \"pmids\": [\"33789098\", \"34599155\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SIRT2 regulation operates in vivo during tumorigenesis unknown\", \"Mechanism by which BRCA1 resolves centromeric R-loops not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked BRCA1 transcriptional control to ferroptosis vulnerability, showing it activates VDAC3 and GPX4 and that BRCA1 deficiency creates a GPX4-inhibitor and PARPi synergy via NCOA4-mediated ferritinophagy.\",\n      \"evidence\": \"Reporter assays, ChIP, viability assays with GPX4i/PARPi, NCOA4 knockdown, xenografts\",\n      \"pmids\": [\"38552003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect transcriptional control of VDAC3/GPX4 not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRCA1's many activities\\u2014HR, transcription, ubiquitin ligation toward diverse substrates, R-loop resolution, and chromatin maintenance\\u2014are coordinated within distinct complexes and which are most critical for tumor suppression remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking ligase activity to HR in vivo\", \"Relative tumor-suppressive weight of transcriptional vs. repair functions undefined\", \"Substrate selectivity rules for BRCA1/BARD1 unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [3, 5, 9, 11, 15]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 11, 15]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 12, 21]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [8, 12, 15]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 6, 20]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [2, 15, 17]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 10, 5]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 11, 12, 21]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 15, 17]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 20]}\n    ],\n    \"complexes\": [\n      \"BRCA1-BARD1 heterodimer\",\n      \"BRCA1-A complex (RAP80/Abraxas/MERIT40/BRCC45)\",\n      \"BRCA1/E2F1/Rb repressive complex\"\n    ],\n    \"partners\": [\n      \"BARD1\",\n      \"ATR\",\n      \"RAP80\",\n      \"CCDC98\",\n      \"MERIT40\",\n      \"BAP1\",\n      \"SIRT2\",\n      \"PALB2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}